Bristol-Myers' next-gen HIV med gets FDA 'breakthrough' designation

Bristol-Myers Squibb ($BMY) nabbed a "breakthrough" tag from the FDA for its next-gen HIV therapy aimed at patients who become resistant to the drugs now in use. The U.S.-based company now gains an inside track at the agency for BMS-663068, an oral "attachment inhibitor" that has demonstrated promising results in a Phase IIb trial. More from FierceBiotech

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.